person · Reporting owner
Primiano Christopher Brett
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | Chief Business Officer | October 28, 2021 | October 29, 2021 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | EVP, CBO, GC & Secretary | December 01, 2020 | December 03, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date October 28, 2021 · Filed October 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,750 |
Reported balance
After 2021-10-28 transaction · row 1
1 source rowRow 1 · 2021-10-28 · Grant · Acquired 8,750 · Balance 8,750 F1: These shares were acquired pursuant to a restricted stock unit award under the Company's 2021 Stock Option and Incentive Plan. Each restricted stock unit represents the right to receive one share of the Company's common stock. These restricted stock units vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2031-10-27 | Direct | 37,500 |
Reported balance
After 2021-10-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-10-28 · Grant · Acquired 37,500 · Balance 37,500 F2: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 28, 2022 with the remainder vesting thereafter in annual installments. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired pursuant to a restricted stock unit award under the Company's 2021 Stock Option and Incentive Plan. Each restricted stock unit represents the right to receive one share of the Company's common stock. These restricted stock units vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant.
F2: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 28, 2022 with the remainder vesting thereafter in annual installments.
Karyopharm Therapeutics Inc.
Report date December 01, 2020 · Filed December 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,523 |
Ending reported balance
After 2020-12-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-12-01 · Exercise / conversion · Acquired 78,124 · Balance 82,647 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 2 · 2020-12-01 · Sale · Disposed 78,124 · Balance 4,523 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 3 · 2020-12-01 · Exercise / conversion · Acquired 58,937 · Balance 63,460 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 4 · 2020-12-01 · Sale · Disposed 58,937 · Balance 4,523 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.45 · Expires 2028-01-23 | Direct | 46,876 |
Reported balance
After 2020-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-01 · Exercise / conversion · Disposed 78,124 · Balance 46,876 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.39 · Expires 2027-01-19 | Direct | 16,842 |
Reported balance
After 2020-12-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-01 · Exercise / conversion · Disposed 58,937 · Balance 16,842 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F3: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 28, 2021 Filed Oct 29, 2021 23:23 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 37,500 | Not disclosed Strike: $14.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-042078 · doc4.xml · derivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2031-10-27 F2 · price: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 28, 2022 with the remainder vesting thereafter in annual installments. F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 28, 2022 with the remainder vesting thereafter in annual installments. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 23:23 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042078 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2021 Stock Option and Incentive Plan. Each restricted stock unit represents the right to receive one share of the Company's common stock. These restricted stock units vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 58,937 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-20-061537 · doc4.xml · derivative · entry 6 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,842 Underlying: Common Stock · 58,937 shares Expires 2027-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 78,124 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-20-061537 · doc4.xml · derivative · entry 5 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,876 Underlying: Common Stock · 78,124 shares Expires 2028-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 58,937 | $17.35 | $1,022,556.95 |
DisclosureSEC source: 0001209191-20-061537 · doc4.xml · nonDerivative · entry 4 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,523 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 58,937 | $10.39 | $612,355.43 |
DisclosureSEC source: 0001209191-20-061537 · doc4.xml · nonDerivative · entry 3 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 78,124 | $17.66 | $1,379,669.84 |
DisclosureSEC source: 0001209191-20-061537 · doc4.xml · nonDerivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,523 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 78,124 | $10.45 | $816,395.80 |
DisclosureSEC source: 0001209191-20-061537 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:09 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 772 | $14.92 | $11,518.24 |
DisclosureSEC source: 0001209191-20-056883 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,523 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 646 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2020. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 22:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 721 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-20-054825 · doc4.xml · derivative · entry 6 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,779 Underlying: Common Stock · 721 shares Expires 2027-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 22:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 38,550 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-20-054825 · doc4.xml · derivative · entry 5 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,250 Underlying: Common Stock · 38,550 shares Expires 2029-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 22:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 721 | $17.20 | $12,401.20 |
DisclosureSEC source: 0001209191-20-054825 · doc4.xml · nonDerivative · entry 4 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,649 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 22:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 721 | $10.39 | $7,491.19 |
DisclosureSEC source: 0001209191-20-054825 · doc4.xml · nonDerivative · entry 3 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 22:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 38,550 | $16.85 | $649,567.50 |
DisclosureSEC source: 0001209191-20-054825 · doc4.xml · nonDerivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,649 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 22:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 38,550 | $9.21 | $355,045.50 |
DisclosureSEC source: 0001209191-20-054825 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 12:49 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,054 | $0.00 Strike: $6.54 | $0.00 |
DisclosureSEC source: 0001209191-20-049920 · doc4.xml · derivative · entry 3 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,054 shares Expires 2026-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 15, 2017, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 12:49 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,054 | $14.98 | $150,608.92 |
DisclosureSEC source: 0001209191-20-049920 · doc4.xml · nonDerivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,649 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 12:49 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,054 | $6.54 | $65,753.16 |
DisclosureSEC source: 0001209191-20-049920 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:25 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 2,946 | $0.00 Strike: $6.54 | $0.00 |
DisclosureSEC source: 0001209191-20-028268 · doc4.xml · derivative · entry 4 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,054 Underlying: Common Stock · 2,946 shares Expires 2026-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 15, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:25 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,946 | $20.00 | $58,920.00 |
DisclosureSEC source: 0001209191-20-028268 · doc4.xml · nonDerivative · entry 3 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,649 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:25 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 2,946 | $6.54 | $19,266.84 |
DisclosureSEC source: 0001209191-20-028268 · doc4.xml · nonDerivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:25 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 6,714 | $19.62 | $131,707.20 |
DisclosureSEC source: 0001209191-20-028268 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,649 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.37 to $20.00, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 996 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 01:33 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 26,500 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-20-016416 · doc4.xml · derivative · entry 5 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,500 Underlying: Common Stock · 26,500 shares Expires 2027-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 01:33 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 9,000 | $24.00 | $216,028.80 |
DisclosureSEC source: 0001209191-20-016416 · doc4.xml · nonDerivative · entry 4 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,367 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.04, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 01:33 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $28.00 | $280,000.00 |
DisclosureSEC source: 0001209191-20-016416 · doc4.xml · nonDerivative · entry 3 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,367 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 01:33 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 7,500 | $23.50 | $176,250.00 |
DisclosureSEC source: 0001209191-20-016416 · doc4.xml · nonDerivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,367 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 01:33 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 26,500 | $10.39 | $275,335.00 |
DisclosureSEC source: 0001209191-20-016416 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,867 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:55 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,961 | $16.48 | $48,802.91 |
DisclosureSEC source: 0001209191-20-011692 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,367 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 19, 2020 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 9,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010750 · doc4.xml · derivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,025 Underlying: Common Stock · 9,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F2 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 38,700 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date. F2 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 38,700 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 9,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-010750 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantRestricted Stock Units · Derivative | 30,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007502 · doc4.xml · derivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,300 Underlying: Common Stock · 30,300 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 81,200 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007502 · doc4.xml · derivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,200 Underlying: Common Stock · 81,200 shares Expires 2030-02-04 F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 14:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-19-062196 · doc4.xml · derivative · entry 3 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 14:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 5,000 | $20.00 | $100,000.00 |
DisclosureSEC source: 0001209191-19-062196 · doc4.xml · nonDerivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,653 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 14:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 5,000 | $10.39 | $51,950.00 |
DisclosureSEC source: 0001209191-19-062196 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 22:18 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-19-059914 · doc4.xml · derivative · entry 7 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 22:18 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.54 | $0.00 |
DisclosureSEC source: 0001209191-19-059914 · doc4.xml · derivative · entry 6 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 5,000 shares Expires 2026-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 15, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 22:18 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,000 | $17.46 | $52,368.00 |
DisclosureSEC source: 0001209191-19-059914 · doc4.xml · nonDerivative · entry 5 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,653 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.345 to $17.685, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 22:18 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 5,000 | $17.45 | $87,256.00 |
DisclosureSEC source: 0001209191-19-059914 · doc4.xml · nonDerivative · entry 4 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,653 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.35 to $17.62, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 22:18 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 5,000 | $17.46 | $87,284.00 |
DisclosureSEC source: 0001209191-19-059914 · doc4.xml · nonDerivative · entry 3 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,653 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.34 to $17.61, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 22:18 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 5,000 | $10.39 | $51,950.00 |
DisclosureSEC source: 0001209191-19-059914 · doc4.xml · nonDerivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 22:18 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 5,000 | $6.54 | $32,700.00 |
DisclosureSEC source: 0001209191-19-059914 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 3,772 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:29 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantRestricted Stock Units · Derivative | 38,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011084 · doc4.xml · derivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common Stock · 38,700 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:29 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 102,800 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-19-011084 · doc4.xml · derivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,800 Underlying: Common Stock · 102,800 shares Expires 2029-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 22:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-18-050553 · doc4.xml · derivative · entry 5 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 22:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.54 | $0.00 |
DisclosureSEC source: 0001209191-18-050553 · doc4.xml · derivative · entry 4 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 5,000 shares Expires 2026-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 15, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 22:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $18.90 | $189,046.00 |
DisclosureSEC source: 0001209191-18-050553 · doc4.xml · nonDerivative · entry 3 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,881 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.27 to $19.08, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 22:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 5,000 | $10.39 | $51,950.00 |
DisclosureSEC source: 0001209191-18-050553 · doc4.xml · nonDerivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 22:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 5,000 | $6.54 | $32,700.00 |
DisclosureSEC source: 0001209191-18-050553 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 10, 2018 Filed May 10, 2018 20:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,000 | $18.01 | $36,024.00 |
DisclosureSEC source: 0001209191-18-029243 · doc4.xml · nonDerivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,881 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in transactions at $18.00 and $18.06. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.